We are writing to highlight the findings of a recent meta-analysis suggesting a possible relationship between the long-term use of angiotensin-converting enzyme inhibitors (ACEIs) and an increased risk of lung cancer [1]. ACEIs are commonly prescribed for hypertension, myocardial infarction, heart failure and renal disease due to improvements in both morbidity and mortality. ACEIs are generally considered safe and associated with significant patient adherence amongst antihypertensive medications, however, emerging evidence implies a nuanced interplay between these medications and lung cancer risk.
